Population-based age-specific incidences of cytogenetic subgroups of acute myeloid leukemia

Haematologica

Volumn 90, Issue 11, 2005, Pages 1502-1510

  Bacher, Ulrike ^a   Kern, Wolfgang ^a   Schnittger, Susanne ^a   Hiddemann, Wolfgang ^a   Haferlach, Torsten ^a   Schoch, Claudia ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Acute myeloid leukemia (AML); Age specific incidences; Cytogenetic sub groups; Molecular markers

Indexed keywords

FLT3 LIGAND; MIXED LINEAGE LEUKEMIA PROTEIN; ONCOPROTEIN; PROTEIN TYROSINE KINASE; RAS PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CHROMOSOME ABERRATION; CONTROLLED STUDY; CYTOGENETICS; FEMALE; GENE MUTATION; GENE TRANSLOCATION; GENETIC MARKER; HUMAN; HUMAN CELL; INCIDENCE; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; ONCOGENE N RAS; POPULATION GENETICS;

ADULT; AGE FACTORS; AGED; CYTOGENETICS; FEMALE; GENETIC MARKERS; GENETICS, POPULATION; HUMANS; INCIDENCE; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; TRANSLOCATION, GENETIC;

EID: 27844457594     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. De Pinho R. The age of cancer. Nature 2000;408:248-54.
2. Greaves M. Molecular genetics, natural history and the demise of childhood leukaemia. European Journal of Cancer 1999;35:173-85.
3. Johansson B MPMF. Primary vs. secondary neoplasia-associated chromosomal abnormalities-balanced rearrangements vs. genomic imbalances? Genes Chromosomes Cancer 1996;16:155-63.
4. Knudson AG. Two genetic hits (more or less) to cancel. Nature Rev Cancer 2001;1:157-62.
5. Lengauer C KKVB. Genetic instabilities in human cancers. Nature 1998;396:643-9.
6. Renan MJ. How many mutations are required for tumorigenesis - implications from human cancer data. Mol Carcinogenes 1993;7:139-46.
7. Grimwade D, Walker H, Oliver P, Wheatley K, Harrison C. Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 1998;92:2322-33.
8. Schoch C, Haferlach T. Cytogenetics in acute myeloid leukemia. Current Oncology Reports 2002;4:390-7.
9. Schoch C, Kern W, Krawitz P, Dugas M, Schnittger S, Haferlach T, et al. Dependence of age-specific incidence of acute myeloid leukemia on karyotype. Blood 2001;98:3500.
10. Swansbury GJ, Lawler SD, Alimena G. Long-term survival in acute myelogenous leukemia: a second follow-up of the Fourth International Workshop on Chromosomes in Leukemia. Cancer Genet Cytogenet 1994 1994;73:l-7.
11. Bloomfield CD, Herzig GP, Caligiuri MA. Introduction: acute leukemia: recent advances. Semin Oncol 1997;24:1-2.
12. Mrozek K, Heinonen K, dela Chapelle A, Bloomfield CD. Clinical significance of cytogenetics in acute myeloid leukemia. Semin Oncol 1997;24:17-31.
13. Moorman AV, Roman E, Willett EV, Dovey GJ, Cartwright RA, Morgan GJ. Karyotype and age in acute myeloid leukemia. Are they linked? Cancer Genet Cytogenet 2001;126:155-161.
14. Schoch C, Schnittger S, Klaus M, Kern W, Hiddemann W, Haferlach T. AML with llq23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. Blood 2003;102:2395-402.
15. Schoch C, Haferlach T, Haase D, Fonatsch C, Loffler H, Schlegelberger B, et al. Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients. Br J Haematol 2001;112:118-26.
16. Kottaridis PD, Gale RE, Langabeer SE, Frew ME. Bowen DT, Linch DC. Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. Blood 2002;100:2393-8.
17. Schnittger S, Schoch C, Dugas M, Kern W, Staib P, Wuchter C, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002;100:59-66.
18. Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, Platzbecker U, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of sub-groups with poor prognosis. Blood 2002;99:4326-35.
19. Yamamoto Y Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S, et al. Activating mutation or D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001;97:2434-9.
20. Yokota S, Kiyoi H, Nakao M, Iwai T, Misawa S, Okuda T, et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 1997;11:1605-9.
21. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002;100:1532-42.
22. Schnittger S, Schoch C, Kern W, Hiddemann W, Haferlach T. FLT3 length mutations as marker for follow-up studies in acute myeloid leukaemia. Acta Haematologica 2004;112:68-78.
23. Zwaan CM, Meshinchi S, Radich JP, Veerman AJP, Huismans DR, Munske L, et al. FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. Blood 2003;102:2387-94.
24. Schnittger S, Kinkelin U, Schoch C, Heinecke A, Haase D, Haferlach T, et al. Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML. Leukemia 2000;14:796-804.
25. Beghini A, Larizza L, Cairoli R, Morra E. c-kit activating mutations and mast cell proliferation in human leukemia. Blood 1998;92:701-2.
26. Longley BJ, Reguera MJ, Ma YS. Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. Leuk Res 2001;25:571-6.
27. Ning ZQ, Li J, Arceci RJ. Activating mutations of c-kit at codon 816 confer drug resistance in human leukemia cells. Leuk Lymphoma 2001;41:513-22
28. Frohling S, Schlenk RE, Stolze I, Bihlmayr J, Benner A, Kreitmeier S, et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol 2004;22:624-33.
29. Leroy H, Roumier C, Huyghe P, Biggio V, Fenaux P, Preudhomme C. CEBPA point mutations in hematological malignancies. Leukemia 2005;19:329-34.
30. Pabst T, Mueller BU, Zhang P, Radomska HS, Narravula S, Schnittger S, et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-α (C/EBPα), in acute myeloid leukemia. Nature Genetics 2001;27:263-70.
31. Janssen JW. RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes. Proc Natl Acad Sci USA 1987;84:9228-332.
32. Neubauer A, Dodge RK, George SL, Davey FR, Silver RT, Schiffer CA, et al. Prognostic importance of mutations in the Ras protooncogenes in de novo acute myeloid leukemia. Blood 1994;83:1603-11.
33. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005;352:254-66.
34. Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S, et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999;93:3074-80.
35. Dormer K, Tobis K, Ulrich R, Frohling S, Benner A, Schlenk RF, et al. Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the acute myeloid leukemia study group Ulm. J Clin Oncol 2002;20:3254-61.
36. Preudhomme C, Grardel N, Huyghe P, Rounder C, Lai JL, Debotton S, et al. Evaluation of minimal residual disease (MRD) by competitive quantitative PCR using IgH/TCR rearrangements has prognostic value in adult acute lympnoblastic-leukemia (ALL): a single center study. Blood 2001;98:315A.
37. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976;33:451-8.
38. Schoch C, Schnittger S, Bursch S, Gerstner D, Hochhaus A, Berger U, et al. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia 2002;16:53-9.
39. Schoch C, Kern W, Kohlmann A, Hiddemann W, Schnittger S, Haferlach T. Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile. Genes Chromosomes Cancer 2005;43:227-38.
40. Lowenberg B, Downing JR, Burnett A. Medical progress. Acute myeloid leukemia. N Engl J Med 1999;341:1051-62.
41. Head DR. Revised classification of acute myeloid leukemia. Leukemia 1996;10:1826-31.
42. Mauritzson N, Johansson B, Albin M, Billstrom R, Ahlgren T, Mikoczy Z, et al. A single-center population-based consecutive series of 1500 cytogenetically investigated adult hematological malignancies: karyotypic features in relation to morphology, age and gender. Eur J Haematol 1999;62:95-102.
43. Preiss BS, Kerndrup GB, Schmidt KG, Sorensen AG, Clausen NAT, Gadeberg OV, et al. Cytogenetic findings in adult de novo acute myeloid leukaemia. A population-based study of 303/337 patients. Br J Haematol 2003;123:219-34.
44. Vickers M, Jackson G, Taylor P. The incidence of acute promyelocytic leukemia appears constant over most of a human lifespan, implying only one rate limiting mutation. Leukemia 2000;14:722-6.
45. Dutrillaux B. Chromosome and gene alterations in human cancers in relation to aging. Chromosomes Today 2000;13:207-13.
46. Ford AM, Bennett CA, Price CM, Bruin MC,Van Wering ER, Greaves M. Fetal origins of the TEL-AML1 fusion gene in identical twins with leukemia. Proc Natl Acad Sci USA 1998;59:4584-8.
47. Greaves MF. Aetiology of acute leukaemia. Lancet 1997;349:344-9.
48. Wiemels JL, Xiao ZJ, Buffler PA, Maia AT, Ma XM, Dicks BM, et al. In utero origin of t(8;21) AML1-ETO translocations in childhood acute myeloid leukemia. Blood 2002;99:3801-5.
49. Mchale CM, Wiemels JL, Zhang LP, Ma XM, Buffler PA, Feusner J, et al. Prenatal origin of childhood acute myeloid leukemias harboring chromosomal rearrangements t(15;17) and inv(16). Blood 2003;101:4640-1.
50. Gisselsson D, Pettersson L, Hoglund M, Heidenblad M, Gorunova L, Wiegant J, et al. Chromosomal breakage-fusion-bridge events cause genetic intratumor heterogeneity. Proc Natl Acad Sci USA 2004-97:5357-62.
51. Nicklas RB. How cells get the right chromosomes. Science 1997;275:632-7.
52. Obe G, Pfeiffer P, Savage JR, Johannes C, Goedecke W, Jeppesen P, et al. Chromosomal aberrations: formation, identification and distribution. Mut Res 2002;504:17-36.
53. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525-32.
54. Libura M, Asnafi V, Tu A, Delabesse E, Tigaud I, Cymbalista F, et al. FLT3 and MIL intragenic abnormalities in AML reflect a common category of genotoxic stress. Blood 2003;102:2198-204.